Vasoactive intestinal peptide in pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 7, 2012, Pages 786-

  Said, Sami I ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTERIAL OXYGEN SATURATION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LETTER; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SINGLE DRUG DOSE; TREATMENT OUTCOME; DRUG EFFECT; VASCULAR RESISTANCE;

HUMANS; HYPERTENSION, PULMONARY; VASCULAR RESISTANCE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84859495387     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.185.7.786     Document Type: Letter

References (3)

1. Galie N, Boonstra A, Ewert R, Gomez-Sanchez MA, Barbera JA, Torbicki A, Bremer H, Ghofrani A, Naeije R, Gruenig E, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH) [abstract]. Am J Respir Crit CareMed 2010;181:A2516.
2. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-1346. (Pubitemid 36554704)
3. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008;32:1289-1294.